Integer Holdings Co. (NYSE:ITGR) Stake Lifted by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 0.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,835,570 shares of the medical equipment provider's stock after acquiring an additional 8,473 shares during the quarter. Vanguard Group Inc. owned 11.44% of Integer worth $508,290,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Glenmede Trust Co. NA purchased a new position in shares of Integer in the third quarter valued at $308,000. Captrust Financial Advisors grew its holdings in Integer by 24.9% during the 3rd quarter. Captrust Financial Advisors now owns 7,675 shares of the medical equipment provider's stock valued at $998,000 after buying an additional 1,530 shares during the last quarter. Verition Fund Management LLC increased its position in Integer by 17.4% during the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider's stock worth $451,000 after buying an additional 515 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of Integer in the third quarter worth $259,000. Finally, Bamco Inc. NY lifted its position in shares of Integer by 17.4% in the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider's stock valued at $33,069,000 after acquiring an additional 37,700 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. KeyCorp boosted their target price on shares of Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Truist Financial lifted their target price on shares of Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Citigroup increased their price target on Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a research note on Wednesday, December 11th. Oppenheimer downgraded Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Finally, Raymond James started coverage on shares of Integer in a research note on Friday, March 28th. They set an "outperform" rating and a $145.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $148.56.

Remove Ads

Integer Stock Down 1.9 %

ITGR traded down $2.20 on Friday, reaching $113.87. The company's stock had a trading volume of 1,211,284 shares, compared to its average volume of 332,815. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. Integer Holdings Co. has a 1 year low of $107.11 and a 1 year high of $146.36. The business's 50 day moving average is $128.00 and its 200 day moving average is $131.75. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of 33.89, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. As a group, research analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.